Celgene

Celgene bags option on Nimbus' anticancer HPK1 inhibitor
Celgene bags option on Nimbus' anticancer HPK1 inhibitor
Fierce Biotech
Celgene
Nimbus Therapeutics
HPK1 inhibitors
Flag link:
Why Bristol-Myers Squibb Stock Plunged in the First Half of 2019
Why Bristol-Myers Squibb Stock Plunged in the First Half of 2019
Motley Fool
Bristol-Myers Squibb
Celgene
M&A
Flag link:
FDA Action Alert: Karyopharm, Merck and Celgene
FDA Action Alert: Karyopharm, Merck and Celgene
BioSpace
FDA
Karyopharm
Selinexor
Merck
relebactam
Celgene
Otezla
Flag link:
The 2 Biggest Casualties From the Celgene-Bristol-Myers Merger (So Far)
The 2 Biggest Casualties From the Celgene-Bristol-Myers Merger (So Far)
Yahoo/Motley Fool
Bristol-Myers Squibb
Celgene
M&A
BeiGene
tislelizumab
Otezla
Flag link:
Bristol-Myers Squibb: Losing Otezla Might Be Challenging
Bristol-Myers Squibb: Losing Otezla Might Be Challenging
Market Realist
Bristol-Myers Squibb
Celgene
M&A
Otezla
Flag link:
FDA Action Alert: Regeneron, Sanofi, Celgene
FDA Action Alert: Regeneron, Sanofi, Celgene
BioSpace
FDA
drug approvals
Acer Therapeutics
Edsivo
Regeneron
Sanofi
Dupixent
Celgene
Revlimid
Alexion
Soliris
Dova Pharmaceuticals
Doptelet
Nabriva Therapeutics
Contepo
Retrophin
Thiola
Flag link:
In surprise switch, Bristol-Myers is selling off blockbuster Otezla, promising to complete Celgene acquisition — just later
In surprise switch, Bristol-Myers is selling off blockbuster Otezla, promising to complete Celgene acquisition — just later
Endpoints
Bristol-Myers Squibb
Opdivo
Otezla
M&A
FTC
Celgene
Flag link:
3 Drugs Under FDA Review With Blockbuster Potential
3 Drugs Under FDA Review With Blockbuster Potential
Motley Fool
AbbVie
Upadacitinib
rheumatoid arthritis
Novartis
brolucizumab
wet age-related macular degeneration
Celgene
ozanimod
relapsing multiple sclerosis
Flag link:
What Should Celgene's Investors Do With Everything Bristol-Meyer Squibb Is Giving Them?
What Should Celgene's Investors Do With Everything Bristol-Meyer Squibb Is Giving Them?
Motley Fool
Bristol-Myers Squibb
Celgene
M&A
Flag link:
Meet the Top Ten Drugs of 2024 (Maybe)
Meet the Top Ten Drugs of 2024 (Maybe)
Drug Channels
AbbVie
Humira
Merck
Keytruda
Eliquis
Bristol-Myers Squibb
Imbruvica
Opdivo
Revlimid
Celgene
Flag link:
As Bristol-Myers/Celgene tie up loose ends, BeiGene pockets $150M from PD-1 breakup
As Bristol-Myers/Celgene tie up loose ends, BeiGene pockets $150M from PD-1 breakup
Endpoints
BeiGene
Bristol-Myers Squibb
Celgene
Opdivo
Flag link:
5 Most Valuable Pipeline Drugs in Development -- and the Stocks Poised to Profit
5 Most Valuable Pipeline Drugs in Development -- and the Stocks Poised to Profit
Motley Fool
Vertex Pharmaceuticals
VX-445
tezacaftor/ivacaftor
AbbVie
upadacatinib
Daiichi Sankyo
trastuzumab deruxtecan
Celgene
liso-cel
Novartis
LY3298176
Flag link:
Grail’s Cook Steps Down, Former Juno Executive Bishop Named CEO
Grail’s Cook Steps Down, Former Juno Executive Bishop Named CEO
BioCentury
Grail
diagnostics
Juno Therapeutics
Celgene
Flag link:
Celgene can breathe a sigh of relief as FDA accepts once-spurned ozanimod application — setting a target date on a blockbuster decision
Celgene can breathe a sigh of relief as FDA accepts once-spurned ozanimod application — setting a target date on a blockbuster decision
Endpoints
Celgene
FDA
EMA
ozanimod
multiple sclerosis
Flag link:
BMS reveals its post-Celgene takeover management team
BMS reveals its post-Celgene takeover management team
Pharmaforum
Bristol-Myers Squibb
Celgene
M&A
Flag link:
In a much-needed positive for BMS, Celgene gains FDA review for blockbuster hopeful
In a much-needed positive for BMS, Celgene gains FDA review for blockbuster hopeful
Fierce Biotech
Celgene
Bristol-Myers Squibb
Acceleron
luspatercept
MDS
beta thalassemia
Flag link:
June 3 ASCO Quick Takes: ORR of 32% for Celgene's iberdomide in MM; plus Five Prime, Iovance and more
June 3 ASCO Quick Takes: ORR of 32% for Celgene's iberdomide in MM; plus Five Prime, Iovance and more
BioCentury
ASCO 2019
Celgene
Multiple Myeloma
Five Prime Therapeutics
Iovance
Merck
Moderna Therapeutics
Eli Lilly
ICR
Flag link:
Celgene gets FDA nod for blood cancer drug combo Revlimid plus rituximab
Celgene gets FDA nod for blood cancer drug combo Revlimid plus rituximab
Pharmaceutical Business Review
Celgene
Revlimid
follicular lymphoma
marginal zone lymphoma
Flag link:
Morphosys to take on CAR-Ts in NHL with promising antibody
Morphosys to take on CAR-Ts in NHL with promising antibody
Pharmaforum
MorphoSys
Celgene
Revlimid
non-Hodgkin lymphoma
clinical trials
tafasitamab
Flag link:
After years of delays, NICE backs Celgene’s Revlimid in first-line MM
After years of delays, NICE backs Celgene’s Revlimid in first-line MM
Pharmaforum
Celgene
Revlimid
Multiple Myeloma
NICE
NHS
England
Flag link:

Pages